Table 2. Clinical characteristics of six patients assessed by follow-up study.
| Patient | Breed | Age | Gender | Tumor site | Stagea | Metastasis site | Treatment | ST (days) |
|---|---|---|---|---|---|---|---|---|
| 1 | MP | 9 | Spayed | Bladder | T2N0M0 | No | Surgery+cox2i | 22 |
| 2 | PM | 13 | Spayed | Bladder | T2N0M0 | No | Surgery+cox2i | 228* |
| 3 | PM | 8 | Spayed | Bladder | T2N0M0 | No | Chemotherapy+cox2i | 305 |
| 4 | Pug | 11 | Spayed | Bladder+ urethra | T3N0M1 | Pelvic bone | Chemotherapy+cox2i | 217 |
| 5 | MD | 13 | Spayed | Bladder | T3N0M0 | No | Chemotherapy+cox2i | 340* |
| 6 | SS | 12 | Castrated | Bladder | T2N0M1 | Lung | Chemotherapy+cox2i | 335* |
a) According to the WHO staging system [12].
*: censored case
MP, miniature pinscher; PM, pomeranian; MD, miniature dachshund; SS, shetland sheepdog; ST, survival time; cox2i, cyclooxygenase2 inhibitor